HB0939 requires the Maryland Commission for Women to create the Maryland Collaborative to Advance Implementation of Coverage of Over-the-Counter Birth Control. The collaborative is charged with studying how Maryland can improve access to over-the-counter contraception and with developing recommendations for implementation, education, and outreach. Its work is focused on practical ways to make coverage work at the point of sale and across different purchasing channels, including pharmacies, retail counters, online platforms, and vending machines.
The collaborative must include representatives from state agencies, health programs, insurers, pharmacy and retail stakeholders, reproductive health organizations, and consumer-focused groups. It is directed to review federal guidance and recent reports on over-the-counter birth control coverage, consult with relevant industry and community entities, and issue an interim report by January 1, 2026, and a final report by December 1, 2027. The act takes effect July 1, 2025, and is temporary, expiring June 30, 2028.
The bill’s main legal effect is to create a new temporary advisory body within state government and to formalize a study process around implementation of existing and future coverage requirements for over-the-counter birth control. It does not itself mandate new insurance benefits or change substantive coverage rules, but it may influence how Maryland administers contraceptive coverage under state-regulated private plans, Medicaid, and the State Employee and Retiree Health and Welfare Benefits Program. It also implicates pharmacies, insurers, pharmacy benefit managers, managed care organizations, and retail sellers of contraception.
The overall sentiment reflected in the bill text is strongly supportive of expanding access to birth control and of Maryland continuing to lead on reproductive health policy. The preamble emphasizes reproductive freedom, autonomy, and the need to reduce barriers to access. Because there are no committee transcripts or recorded votes provided, there is no direct evidence of opposition or debate in the available materials.
The main point of contention, based on the structure of the bill, is likely to be implementation rather than the general goal of access: how coverage should work at pharmacies and retail counters, how point-of-sale reimbursement should be handled, and how insurers, PBMs, and retailers should coordinate. The bill anticipates those issues by bringing together stakeholders with potentially differing operational and financial interests, including reproductive justice advocates, insurers, retailers, pharmacies, and health agencies.
HB0939 adds a temporary, cross-sector collaborative under the Maryland Commission for Women to study and recommend ways to implement coverage of over-the-counter birth control. It does not directly amend insurance mandates or Medicaid eligibility, but it is intended to inform future administration of coverage requirements affecting state-regulated private health plans, the Maryland Medical Assistance Program, and the State Employee and Retiree Health and Welfare Benefits Program. The bill also creates reporting obligations and a sunset date, making the collaborative a time-limited policy-development mechanism rather than a permanent program.
The bill appears broadly favorable and policy-driven, with a clear pro-access and pro-reproductive-freedom orientation. Its findings and purpose language frame over-the-counter birth control as an access and autonomy issue, and the bill positions Maryland as a national leader in implementation. No vote totals, hearing testimony, or transcript excerpts were provided, so the available record does not show organized opposition or divided committee sentiment.
The likely areas of disagreement are operational and fiscal rather than ideological: whether coverage should be implemented at the pharmacy counter, through online retail, or through vending machines; how reimbursement and claims processing should work; and how to coordinate among insurers, pharmacy benefit managers, retailers, and state programs. Stakeholders with different roles in the health care and retail systems may have competing views on administrative burden, payment timing, consumer access, and compliance requirements. Reproductive health advocates are likely to favor broader, easier access, while insurers, PBMs, and retailers may focus on feasibility and cost.